Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model
Pilot Study Demonstrates 50% Survival in Valortim-Treated Animals
03-Apr-2007 -
Medarex, Inc. and PharmAthene, Inc. announced that Valortim(TM), a fully human monoclonal antibody product candidate being developed for the prevention and treatment of anthrax infection, has been shown to have a therapeutic effect in a new primate model of established inhalation anthrax ...
anthrax
food
infectious diseases
+2